Skip to main content
TipRanks
Go Ultimate75% OFF

CapsoVision, Inc. (CV) AI Stock Analysis

27 Followers
CV

CapsoVision, Inc.

(NASDAQ:CV)

Select Model
Rating:50Neutral
Price Target:$7.00▲(2.64% Upside)
Action:reiterated
Date:11/13/26

The score is held back primarily by weak financial performance—very large operating losses and heavy cash burn—despite strong revenue growth and low current leverage. Technicals are also soft with the stock trading below key moving averages and negative MACD. These risks are partially offset by a constructive earnings call focused on meaningful regulatory/product milestones and guidance for improved revenue trajectory into 2H 2026 and 2027.

Positive Factors
Differentiated AI imaging platformThe combination of panoramic small-bowel imaging and FDA-cleared AI review differentiates CapsoVision’s product from competing capsules. This integrated capability may improve physician efficiency, support clinical adoption, and strengthen the company’s competitive position across hospitals and GI practices.
Negative Factors
Significant and worsening cash burnPersistent negative operating and free cash flow means the business is not yet funding operations internally. The worsening burn increases dependence on financing resources, limits flexibility to invest through a downturn, and raises the importance of achieving meaningful revenue scale and expense discipline.

CapsoVision, Inc. (CV) vs. SPDR S&P 500 ETF (SPY)

-50%0%50%100%150%200%CV+29.41%SPY+11.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$365.62M
Dividend Yield
―
Average Volume (3M)
170.85K
Price to Earnings (P/E)
-11.2
Beta (1Y)
-1.15
Revenue Growth
―
EPS Growth
―
Country
US
Employees
99
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

CapsoVision, Inc. Business Overview & Revenue Model

Company Description

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of t...

CapsoVision, Inc. Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:8.77%|Next Earnings Date:Apr 01, 2027
Earnings Call SentimentPositive

The call was predominantly positive, driven by FDA clearance and the U.S. launch of AI Highlights, completion of the CapsoCam Colon clinical study, new account growth, expanding patient utilization, financing resources and progress in the pancreatic cancer pipeline. The primary negatives were the competitive U.S. pricing environment, only 1% year-over-year revenue growth, lower gross profit and gross margin, and the company's continuing net loss. Overall, the milestones and strategic progress significantly outweighed the financial and commercial challenges.

Positive Updates

FDA Clearance and U.S. Launch of AI Highlights
AI Highlights for CapsoCam Plus received FDA clearance on September 25 and officially launched in the U.S. on November 2. Management described the clearance and launch as a major achievement and a way to strengthen CapsoVision's position in small bowel endoscopy.

Negative Updates

Competitive U.S. Pricing Environment
Management said the third quarter reflected a competitive pricing environment in the U.S. for small bowel capsule endoscopy, even as the company continued expanding its customer base.

Company Guidance

CapsoVision remains on track for submitting CapsoCam Colon before year-end 2026; the initial U.S. annual addressable market is approximately $1 billion, with the longer-term opportunity estimated to be over $10 billion. The company expects associated clinical expenses to decrease, providing an opportunity for a further operating expense decline, and believes revenue in the second half of 2026 will be higher than the first half; with AI Highlights launched on November 2, it expects sales of CapsoCam Plus to accelerate with the full impact realized in 2027. Site activation is advancing over dozen large volume centers, data will be available next month, and the company plans to commence the esophageal varices trial in the second half of next year.

CapsoVision, Inc. Financial Statement Overview

Summary

Revenue growth and solid gross margins are positives, and leverage is currently low. However, the financial profile is dominated by extremely large operating and net losses and significant, worsening cash burn, which elevates near-term funding and operating leverage risk.

Income Statement

26Negative

Balance Sheet

52Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023
Income Statement
Total Revenue13.92M13.55M11.76M9.75M
Gross Profit6.92M7.17M6.38M5.49M
EBITDA-28.86M-24.95M-19.40M-10.96M
Net Income-29.25M-25.32M-19.90M-11.30M
Balance Sheet
Total Assets32.75M18.16M16.80M21.53M
Cash, Cash Equivalents and Short-Term Investments21.76M10.11M9.32M14.56M
Total Debt780.00K887.00K1.24M1.51M
Total Liabilities6.38M4.90M146.31M131.37M
Stockholders Equity26.37M13.26M-129.51M-109.84M
Cash Flow
Free Cash Flow-29.27M-22.95M-20.24M-11.56M
Operating Cash Flow-29.20M-22.86M-20.09M-10.80M
Investing Cash Flow-78.00K-90.00K-153.00K-754.00K
Financing Cash Flow33.28M23.60M15.07M20.53M

CapsoVision, Inc. Technical Analysis

Technical Analysis SentimentPositive
Last Price6.82

Price Trends

50DMA6.55Positive
100DMA6.50Positive
200DMA6.40Positive

Market Momentum

MACD-0.03Negative
RSI56.13Neutral
STOCH73.61Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CV, the sentiment is Positive. The current price of 6.82 is above the 20-day moving average (MA) of 6.62, above the 50-day MA of 6.55, and above the 200-day MA of 6.40, indicating a bullish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 56.13 is Neutral, neither overbought nor oversold. The STOCH value of 73.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CV.

CapsoVision, Inc. Risk Analysis

CapsoVision, Inc. disclosed 69 risk factors in its most recent earnings report. CapsoVision, Inc. reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

CapsoVision, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CV against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
BSXBSX64Neutral$63.26B18.4113.87%―8.88%25.77%
CNMDCNMD63Neutral$1.43B19.847.07%―1.93%16.93%
TNDMTNDM53Neutral$1.19B-23.72-35.61%―6.73%76.54%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CVCV50Neutral$365.62M-11.18-160.22%―――
LUCDLUCD48Neutral$82.58M-1.02-610.65%―23.60%54.50%
PAVMPAVM26Underperform$12.07M-0.14-58.07%―410.34%-185.92%

* Healthcare Sector Average

Performance Comparison

0%100%CVBSXCNMDTNDMPAVMLUCDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CV and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CVCapsoVision, Inc.6.821.5930.40%
BSXBoston Scientific43.64-53.24-54.95%
CNMDConmed Corporation48.015.2312.23%
TNDMTandem Diabetes Care17.05-4.23-19.88%
PAVMPavmed1.32-8.80-86.96%
LUCDLucid Diagnostics Inc.0.41-0.65-61.60%

CapsoVision, Inc. Corporate Events

Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance

CapsoVision Wins FDA Clearance for AI Endoscopy Tool

Positive
Sep 28, 2026

CapsoVision, Inc., a NASDAQ-listed medical technology company specializing in AI-enabled capsule endoscopy for gastrointestinal disease detection, has built its business around the CapsoCam Plus capsule, supported by its CapsoView review software and...

Business Operations and StrategyPrivate Placements and Financing

CapsoVision Announces $18 Million Direct Stock Offering

Positive
Sep 18, 2026

On September 17, 2026, CapsoVision, Inc. entered into a securities purchase agreement for a registered direct offering of 3,163,444 shares of common stock at $5.69 per share, a roughly 5% discount to the prior Nasdaq closing price. The offer, conduct...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026